Table 3 Univariate analysis in terms of OS (overall survival) and EFI (event free survival) with correction for competing risks and on the total population

 NPM1

Continuous

0.99

0.98–1.00

0.147

 NPM1 nucleolus

No

1

Yes

1.83

0.79–4.27

0.161

 NPM1 with cut-off

> 50%

1

≤50%

1.43

0.69–3.02

0.334

 nAPE1

Continuous

0.99

0.98–1.00

0.344

 cAPE1

Continuous

1.01

0.99–1.02

0.149

 Tumor size

1

1

2

1.35

0.58–3.14

0.491

3 or 4

3.48

0.79–15.44

0.100

 Nodal status

Negative

1

Positive

2.05

0.92–4.58

0.079

 Neo/Adj Anthracyclines

No

1

Yes

1.06

0.47–2.39

0.886

 Neo/Adj Taxanes

No

1

Yes

0.82

0.39–1.69

0.585

OS

HR

95% C.I.

p value

 NPM1 nucleolus

No

1

Yes

1.37

0.59–3.20

0.464

 NPM1 with cut-off

> 50%

1

≤50%

1.25

0.61–2.57

0.541

 nAPE1

Continuous

1

0.99–1.01

0.767

 cAPE1

Continuous

1

0.99–1.01

0.553

 Tumor size

1

1

2

1.73

0.73–4.11

0.214

3 or 4

12.59

4.30–36.84

< 0.001

 Nodal status

Negative

1

Positive

1.47

0.68–3.17

0.328

 Neo/Adj Anthracyclines

No

1

Yes

0.45

0.22–0.91

0.026

 Neo/Adj Taxanes

No

1

Yes

0.50

0.24–1.02

0.055